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ALL NETS ARE EQUAL, BUT SOME NETS ARE MORE EQUAL THAN 
OTHERS
Mark Rowland Editorial Board Member, LSHTM
ating unbiased estimates of effect sizes of new vector control 
tools. Since 2017, WHO has made randomised trial evidence 
a policy requirement before recommending any new class of 
net (WHO 2017). In the Tanzanian trial reported earlier, the 
villages that were randomised to receive the pyrethroid-PBO 
synergist net recorded a prevalence of malaria infection after 
9 months of use 44% less than the villages randomised to the 
standard pyrethroid LLIN (prevalence ratio 0.56, 95% confi-
dence interval 0.40–0.77) (Protopopoff et al. 2018). After 21 
months of use, the prevalence was still 33% less (PR 0.67, 
CI 0.50–0.90). On the basis of these results, WHO awarded 
interim ‘new vector control product class’ status to pyrethroid-
PBO ITN. In response to the WHO recommendation, the main 
international malaria control agencies – the Global Fund and 
the US Present’s Malaria Initiative (PMI) – started to place 
orders for this new class of net. 
Before giving recommendation to a new product class 
WHO normally expects randomised trial evidence from two 
studies from different places. While the WHO made an excep-
tion owing to the pressing need to introduce a new class of 
active net, a second randomised trial of pyrethroid-PBO ITN 
has recently reported results from Uganda (Staedke et al. 
2019a1). What did it show? This trial was innovative for being 
embedded within the national LLIN distribution campaign 
across over a hundred clusters (health sub-districts) of the 
East and West Regions of Uganda (Staedke et al. 2019b). It 
involved two types of PBO-pyrethroid ITN: Olyset Plus and 
PermaNet 3, and two types of standard pyrethroid only LLIN: 
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It is almost a cliché to open any popular article on malaria 
vector control by attributing much of the dramatic decline 
in malaria in sub-Saharan Africa since 2000 to the massive 
investment in long-lasting insecticide treated nets (LLIN) 
(Bhatt et al. 2015). According to the latest figures from the 
World Health Organization (WHO), over half of Africa’s 
population now has access to LLIN, increasing from 33% 
in 2010 to 57% in 2019 (WHO 2019). In 2018 alone, 197 
million LLINs were delivered to Africa by manufacturers. 
Despite this, LLIN coverage has improved only marginally 
since 2015. The malaria burden worldwide has fallen only 
slightly from an estimated 231 million cases of malaria in 2017 
to 228 million in 2018, and is at a standstill in Africa. Resist-
ance to pyrethroids – the only insecticide class currently used 
routinely in LLIN – is widespread and continues to increase in 
frequency in many countries. While resistance to pyrethroids 
acts as a break on progress it is not the only factor impeding 
progress. The physical durability of the nets (2–3 years before 
nets become holed and unserviceable) is proving shorter than 
the ability of many countries to implement net distribution 
campaigns to the population at risk (3–5 years). Holed nets 
are less protective against mosquitoes that are strongly pyre-
throid resistant (N’Guessan et al. 2007). Holed nets and net 
shortages may lead to periods of inadequate personal and 
community protection, and to temporary increases in malaria 
morbidity between distribution campaigns. 
In an editorial a year ago, we discussed the findings of a clus-
ter-randomised trial of a new type of ITN in which the synergist 
PBO (piperonyl butoxide) and pyrethroid (permethrin) were 
incorporated into the net fibre to overcome resistance to pyre-
throids mediated by mono-oxygenase enzymes (Outlooks on 
Pest Management 2018). Randomised trials are regarded as the 
gold standard for assessing evidence of efficacy and for gener- 1. This is preliminary research that has not been peer-reviewed.
Suite of experimental huts and veranda traps for testing mosquito nets 
and collecting mosquitoes in West Africa.
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Olyset Net and PermaNet 2. Olyset Plus and Olyset Net were 
the same nets trialled earlier in Tanzania. PermaNet 3 differs 
from Olyset Plus in restricting the PBO synergist to the roof 
panel which mosquitoes contact in response to plumes of 
human odour from inside the net. Side panels of PermaNet 3 
are treated with pyrethroid alone (deltamethrin) at a slightly 
higher concentration than in the standard LLIN PermaNet 2. 
PermaNet 3 and PermaNet 2 formed twice as many clusters 
as Olyset Plus and Olyset Net in the 4 arm trial. 
Surveys of malaria parasite infection in children were 
undertaken 6, 12 and 18 months after LLIN distribution to the 
communities. Overall, the prevalence of malaria infection in 
surveys at 6, 12 and 18 months was lower in the PBO arm than 
in the non-PBO arm. In the sub-group analysis stratified by 
manufacturer, the prevalence of malaria infection was lower in 
PermaNet 3 (with PBO) at 6 and 12 months than in PermaNet 
2 but no difference in effect was evident at 18 months. For the 
Olyset arms, malaria infection prevalence was lower in Olyset 
Plus (with PBO) after 12 and 18 months of use compared to 
Olyset Net, and this trend was consistent with that previously 
reported in the Tanzanian trial of Olyset Plus vs Olyset Net 
after surveys at 9 and 21 months. The non-significant differ-
ence between the Olyset Plus and Olyset Net arms in the initial 
post-intervention survey at 6 months in Uganda was consistent 
with the initial survey at 4 months in Tanzania. 
Why is PermaNet 3 effective at 6 and 12 months and 
appears less effective at 18? Why is Olyset Plus effective at 
12 months, still effective at 18 months but seemingly less 
effective at 6-months? Despite some imbalances in the sizes 
of arms and regions which the authors state prevents draw-
ing conclusions between brands, one reason may lie less in 
the epidemiology but more in the initial laboratory assess-
ments of insecticide/PBO durability and retention that was 
commissioned by the WHO Pesticide Evaluation Scheme 
on PermaNet 3 and Olyset Plus in their initial evaluations a 
decade ago (WHO 2009, 2012). To assess the durability and 
wash resistance of active ingredients in a new brand of LLIN, 
the standard WHO practice is to subject samples of netting to 
a series of 20 standardised soap washings and determine every 
3–5 washes the residual insecticide and synergist remaining 
in the netting using chemical analysis and mosquito bioassay. 
The producers of LLINs are careful to balance the loading 
dose and migration of the active ingredients from the ‘reser-
voir’ within the fibre to the surface where it is bioavailable to 
mosquito contact. Migration too fast and reservoir of AI is 
depleted before the nets’ physical lifespan is reached. Migra-
tion too slow and the AI is locked in the fibre reservoir and 
biologically unavailable to the surface. The results showed 
that in the Olyset Plus netting the piperonyl butoxide reten-
tion after 20 washes was 44.2%, corresponding to an aver-
age retention per wash of 96.0%, and continued to migrate 
with further washing. But in the PermaNet 3 roof-netting the 
piperonyl butoxide retention after 20 washes was 76.0%, 
corresponding to a much higher retention per wash of 98.6%, 
and according to the WHO Working Group report ‘after 15 
washes no further release of PBO seemed to occur’. Retention 
of pyrethroid at 20 washes was consistent with that of PBO, 
i.e. 64.1% retention of pyrethroid permethrin in Olyset Plus 
and 89.5% retention of pyrethroid deltamethrin in PermaNet 
3. These trends indicated to the WHO Working Group that 
the migration of active ingredients to the surface of fibre 
appeared less bound in Olyset Plus than in PermaNet 3 over 
the course of 20 washes.
The chemical analysis is direct evidence of AI retention and 
indirect evidence of release to the surface of the fibre. The next 
stage in the WHO assessment of new types of LLINs (Phase 2) 
are experimental hut trials. These are entomological trials done 
under controlled household conditions in special huts in which 
human volunteers sleep under the study nets and free-flying wild 
mosquitoes are attracted into the huts to feed each night. PBO-
pyrethroid LLIN are compared against standard pyrethroid 
LLIN when new and unwashed and after 20 wash cycles. Paral-
lel trials are undertaken across a range of countries to build 
the evidence. What did the field washing and household effi-
cacy trials show? Firstly, that field washes gave retention rates 
consistent with the laboratory washing: PBO retention was 
lower in Olyset Plus at 45% and higher in PermaNet 3 at 78%. 
Similarly, pyrethroid retention was lower at 76% in Olyset Plus 
and higher at 85% in PermaNet 3. Two efficacy outcomes were 
assessed in the huts: mosquito mortality rate and mosquito 
blood feeding rate through the nets. A Cochrane meta-analysis 
summarised the results (Gleave et al. 2018). The comparison 
of PBO nets versus non-PBO nets is presented as summary risk 
ratios of mosquito mortality and blood feeding. Mortality risk 
ratios significantly greater than 1.0 indicate greater control 
of mosquitoes by PBO nets, blood-feeding risk ratios signifi-
cantly less than 1.0 indicate greater personal protection from 
biting by PBO nets. Comparing Olyset Plus versus Olyset Net 
the mortality rate ratio was significantly greater than 1.0 both 
before (1.72, CI 1.48–2.0) and after (1.81, CI 1.25–2.61) the 
series of standardized washing indicating continuing presence 
of surface PBO on Olyset Plus. Comparing PermaNet 3 versus 
PermaNet 2 the mortality risk ratio was significantly greater 
before (1.81, CI 1.56–2.10) but non-significant (1.18, CI 0.61–
2.28) after the washing indicating loss of surface PBO. For the 
blood-feeding risk ratios between Olyset Plus versus Olyset Net 
the ratio was 0.67 (CI 0.38–1.18) before and 0.50 (CI 0.27–
0.93) after washing, and between PermaNet 3 and 2 the risk 
ratio was 0.53 (CI 0.40–0.69 before and 0.76 (CI 0.61–0.93) 
after. Both types of Pyrethroid-PBO LLIN were therefore still 
protective against blood-feeding after washing compared to the 
standard LLIN counterparts. 
The problem flagged up by the review is that few studies 
progressed to comparing washed nets in experimental huts 
which is important to showing PBO migration and retention 
Suite of experimental huts for testing mosquito nets, West Africa.
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at the net surface; only one of the Olyset trials and two of the 
PermaNet trials compared this in high resistance area. No meta-
analysis is definitive or conclusive after so few studies. Also none 
of these experimental hut studies on Olyset Plus and PermaNet 
3 before and after washing was directly comparative at the same 
location at the same time or yielded a complete dataset. It was 
surprising that southern Benin was classified as mid resistance 
in the review (Gleave et al. 2018) when it was the first country 
in West Africa to show operational survival of vector mosqui-
toes due to pyrethroid resistance in experimental huts as early as 
2007 (N’Guessan et al. 2007; 2010). Had the division between 
mid and high resistance been made on the basis of observed 
mortality response in huts to pyrethroid-only nets the division 
between high and mid would have merged giving more power. 
The outcome of the Ugandan trial may confirm WHO recom-
mendation for pyrethroid-PBO LLIN as a new class of LLIN 
and Olyset Plus as the first-in-class following further review. A 
feature common to the two cluster randomised trials in Uganda 
and Tanzania that remains curious is the lag between the distri-
bution of the Olyset Plus and the effect on malaria prevalence. 
The effect is not evident by the time of first survey at 6 months 
in Uganda. PermaNet 3 had a more immediate impact, by the 
6th month survey. In Tanzania a trend was observed at the 4th 
month survey but it was not significant until the 2nd survey done 
in the 9th month (Protopopoff et al. 2018).
WHO Vector Control-Prequalification Team has five 
brands of Pyrethroid-PBO ITNs presently listed for use. 
These include Olyset Plus and PermaNet 3 and three other 
brands made by other manufacturers. In all, there are three 
pyrethroids in use (permethrin, deltamethrin, alpha-cyper-
methrin), two modes of PBO presentation (roof panel only, 
all 5 panels), six dosages of deltamethrin and five dosages 
of PBO. Decisions have to be taken. WHO is not expecting 
each of these brands to undergo epidemiological evaluation 
versus the first-in-class. Time and development costs would 
be prohibitive. Instead, WHO policy is to assess candidate 
2nd-in-class products for entomological efficacy only (WHO 
2018). Due to the significant variation in the specifications of 
the candidates, to generate the required assurance of compar-
ative performance to 1st in class, WHO has designed a non-
inferiority trial design to demonstrate whether each candidate 
2nd-in-class test product is no worse in experimental hut trials 
than the 1st-in-class product by more than a specified non-
inferiority margin defined as an odds ratio of 0.7 between the 
1st- and 2nd-in-class interventions. This value is the maximum 
odds ratio that is considered acceptable for two products to 
be in the same policy class, and is a compromise between 
the risk of accepting an inferior product and the feasibility 
of conducting the trials. To be defined as non-inferior, a new 
product must show non-inferiority in terms of both mosquito 
mortality and blood-feeding rate. Two series of experimen-
tal hut trials of the 5 brands of Pyrethroid-PBO ITN both in 
unwashed state and after 20 standardised washes are due to 
start shortly in Côte d’Ivoire and Tanzania in W and E Africa. 
Because there is a question mark hanging over the veracity 
of 20 standardised washes as a true surrogate of wear-and-
tear under household conditions, it is intended to also supply 
the 5 brands to neighbouring households at the experimental 
hut sites and re-test in the huts after one year of use to verify 
whether they are non-inferior to the 20-times washed nets. 
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